B. Lashner

Publications319
h-index57
Citations12,582
Highly Influential Citations391
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • W. Sandborn
  • 1,901 Publications, 94,323 Citations
  • V. Fazio
  • 710 Publications, 39,132 Citations
  • F. Remzi
  • 394 Publications, 15,377 Citations
  • S. Hanauer
  • 421 Publications, 44,973 Citations
  • Publications
  • Influence
Infliximab maintenance therapy for fistulizing Crohn's disease.
BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab… Expand
  • 1,836
  • 71
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to…
The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical… Expand
  • 396
  • 19
Cytomegalovirus Colitis Complicating Inflammatory Bowel Disease
When patients with inflammatory bowel disease (IBD) are admitted to the hospital with a flare of acute severe colitis, the possibility of a concurrent cytomegalovirus (CMV) infection causing or… Expand
  • 271
  • 15
Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients
BackgroundFew studies have evaluated preoperative infliximab use and postoperative outcomes in Crohn’s patients. Our aim was to evaluate 30-day postoperative outcomes for Crohn’s patients treated… Expand
  • 216
  • 14
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
BACKGROUND & AIMS A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease. METHODS Patients (N = 509) with moderately to… Expand
  • 547
  • 13
The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis
ObjectiveRecent studies have implicated primary sclerosing cholangitis (PSC) as a risk factor for colorectal cancer (CRC) in ulcerative colitis (UC). Our study was designed to define both the risk… Expand
  • 324
  • 11
A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy.
Both medical and surgical therapies for ulcerative colitis have inherent advantages and disadvantages that must be balanced for patients with moderate to severe disease. Restorative proctocolectomy… Expand
  • 186
  • 11
The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis.
BACKGROUND & AIMS Two case-control studies have shown that folate may protect against neoplasia in ulcerative colitis. This historical cohort study was performed to better define this association. … Expand
  • 273
  • 10
Clinical approach to colonic ischemia
Typical clinical manifestations of colonic ischemia include rapid onset of mild abdominal pain and tenderness over the affected bowel, followed by a mild amount of hematochezia within a day of the… Expand
  • 107
  • 10
  • PDF
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
BACKGROUND The endoscopic substudy of the ACCENT I (A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen) Crohn's disease trial examined the effects of… Expand
  • 207
  • 8
  • PDF